diclofenac teva hlaup 23,2 mg/g
teva b.v.* - diclofenacum tvíetýlamín - hlaup - 23,2 mg/g
mirena (levonova) leginnlegg 20 míkróg/24 klst.
bayer ab* - levonorgestrelum inn - leginnlegg - 20 míkróg/24 klst.
emla (emla) krem 25+25 mg/g
aspen pharma trading limited - lidocainum inn; prilocainum inn - krem - 25+25 mg/g
buprenorphine alvogen (buprenorphine ratiopharm) forðaplástur 20 míkróg/klst.
alvogen ehf. - buprenorphinum inn - forðaplástur - 20 míkróg/klst.
fragmin stungulyf, lausn 25.000 and-xa a.e./ml
pfizer aps - dalteparinum natricum inn - stungulyf, lausn - 25.000 and-xa a.e./ml
emla (emla) lyfjaplástur 25+25 mg/plástur
aspen pharma trading limited - lidocainum inn; prilocainum inn - lyfjaplástur - 25+25 mg/plástur
norspan forðaplástur 20 míkróg/klst.
mundipharma a/s - buprenorphinum inn - forðaplástur - 20 míkróg/klst.
pegasys
pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - Ónæmisörvandi, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 og 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. með tilliti til ákvörðun um að hefja meðferð í börn sjúklingar sjá kafla 4. 2, 4. 4 og 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 og 5. fyrir lifrarbólgu c veira (hcv) arfgerð sérstakur starfsemi, sjáðu kafla 4. 2 og 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. Þegar ákveðið að hefja meðferð í æsku, það er mikilvægt að íhuga vöxt hindrunar völdum samsetning meðferð. Á að baka vöxt hindrunar er óvíst. sú ákvörðun að meðhöndla ætti að vera á tilfelli fyrir sig (sjá kafla 4.
rybrevant
janssen-cilag international n.v. - amivantamab - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
sefitude (quietude) húðuð tafla 445 mg
florealis ehf. - valerian root dry extract (3-6:1), ethanol 70 %(v/v) - húðuð tafla - 445 mg